XenoTherapeutics has acquired 2 companies, including 2 in the last 5 years.
The Company’s most targeted sectors include life science (100%).
359 Newbury Street, 5th Floor,
Boston, Massachusetts
02115
United States,
(617) 939-7892
www.xenotx.org
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
|---|---|---|---|---|---|---|
| 2025-11-14 |
Repare Therapeutics · Life Science
Montreal, Quebec · www.reparerx.com Repare Therapeutics is a precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor, as well as CCNE1-SL inhibitor and Polθ inhibitor programs. Repare Therapeutics was founded in 2016 and is headquartered in Montreal, Quebec. Advisors: Cooley , Leerink Partners |
- | Add-on Acquisition |
XenoTherapeutics
|
- |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
